ReviewHealth science reports2026
Epithelial-Myoepithelial Carcinoma of Minor Salivary Glands of the Palate: A Systematic Review.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Epithelial-myoepithelial carcinoma (EMC) is a very rare malignant neoplasm of the salivary glands. It mainly affects the major salivary glands. Little is known about the specificity of EMC in minor salivary glands (MSGs), which represents a diagnostic challenge. Methods: A systematic review was performed to identify clinical cases and case series of EMC in MSGs. The search was restricted to EMC of the palate to better characterize the diagnosis and management of this entity. Results: Of 509 initially identified articles, only 21 were included, involving 25 patients. The lesion was mostly located in the hard palate (56%) and was associated in 20% of cases with a pleomorphic adenoma. All patients received surgical resection. P63 and S-100 were reliable molecular markers. Palatal EMC was associated with the absence of metastasis in 76% of cases. Conclusion: Our study summarizes and updates the clinical features of EMC arising from palatal MSGs. Trial Registeration: CRD42024542994.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.